DENG Xuemei, YANG Wenjun, MA Xian. Research Progress of Bruton’s Tyrosine Kinase Inhibitors in Rheumatoid ArthritisJ. Chinese Journal of Modern Applied Pharmacy. DOI: 10.13748/j.cnki.issn1007-7693.20260995
    Citation: DENG Xuemei, YANG Wenjun, MA Xian. Research Progress of Bruton’s Tyrosine Kinase Inhibitors in Rheumatoid ArthritisJ. Chinese Journal of Modern Applied Pharmacy. DOI: 10.13748/j.cnki.issn1007-7693.20260995

    Research Progress of Bruton’s Tyrosine Kinase Inhibitors in Rheumatoid Arthritis

    • Rheumatoid arthritis(RA) is a chronic autoimmune disease. Clinical studies have confirmed that most patients with RA exhibit abnormal B-cell activation and elevated autoantibodies. Therefore, B-cell-targeted therapeutic strategies have become a research hotspot in the field of RA treatment. Bruton’s tyrosine kinase(BTK) is a critical kinase that regulates the development and maturation of B cells. As novel targeted agents, BTK inhibitors can inhibit the activation of B-cell receptor signaling and thereby modulate immune responses. After being approved for the treatment of B-cell malignancies, BTK inhibitors are currently being investigated for the treatment of a variety of autoimmune diseases including RA. Although they show favorable therapeutic potential against RA in bioactivity assays and animal models, the results at the clinical trial stage exhibit significant differences. On this basis, this paper reviews the structure and function of BTK as well as the latest research progress of BTK inhibitors in the treatment of RA, aiming to provide a reference for the further research and development of BTK inhibitors.
    • loading

    Catalog

      Turn off MathJax
      Article Contents

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return